The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis
Pre-publication versions of this article are available by contacting firstname.lastname@example.org.
|9 Jul 2018||Submitted||Original manuscript|
|25 Jul 2018||Author responded||Author comments - Hui Zhou|
|Resubmission - Version 2|
|25 Jul 2018||Submitted||Manuscript version 2|
|16 Aug 2018||Reviewed||Reviewer Report - Olga Sukocheva|
|5 Sep 2018||Author responded||Author comments - Hui Zhou|
|5 Sep 2018||Reviewed||Reviewer Report - Vladislav Korobeynikov|
|Resubmission - Version 3|
|5 Sep 2018||Submitted||Manuscript version 3|
|10 Sep 2018||Author responded||Author comments - Hui Zhou|
|Resubmission - Version 4|
|10 Sep 2018||Submitted||Manuscript version 4|
|13 Sep 2018||Editorially accepted|
|26 Sep 2018||Article published||10.1186/s12885-018-4817-4|
How does Open Peer Review work?
Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting email@example.com.
You can find further information about the peer review system here.